The importance of collaboration
The complex journey of bringing a biologic to market – part 1 Biologic drugs differ from traditional medicines as they are produced in living systems, making their development and manufacturing ...
NorthX Biologics’ investor and CEO of Flerie, Ted Fjällman made a guest appearance in a recent episode of Värdeskaparna, a podcast taking the audience behind the scenes in the private equity world.
During the podcast, Ted delves into the biotech industry’s current trends and future directions, sharing his valuable insights and experiences.
Click the link below to listen (in Swedish):
Värdeskaparna with Ted Fjällman
NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX Biologics has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies.
For more news, follow us on LinkedIn
The complex journey of bringing a biologic to market – part 1 Biologic drugs differ from traditional medicines as they are produced in living systems, making their development and manufacturing ...
In an increasingly unstable world, Sweden is taking decisive steps to secure access to critical pharmaceuticals during crises and war. As part of a broader government initiative, highlighted in a ...
Bacterially derived extracellular vesicles (EVs) such as Outer Membrane Vesicles (OMVs) have emerged as an attractive new modality for both immunotherapy and as vectors for nucleotides and proteins. Being a ...